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patient reported outcomes as a measure of quality of clinician
reported outcomes appears to be a feasible tactic in a site-based
ratings surveillance quality assurance system.
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OBJECTIVE: Major depressive disorder (MDD) is a leading
cause of disability worldwide. This study analyzed the literature
describing the burden of MDD in North America (USA and
Canada), with particular focus on patients with treatment-
resistant depression (TRD). METHODS: Systematic searches
were conducted of English-language papers published between
1987 and 2007, utilizing MEDLINE, EMBASE, and the
Cochrane Library, relevant websites, and hand searches. Major
areas for review were the humanistic and economic burden of
MDD. Additional areas for analysis included treatment options
and costs, treatment efﬁcacy and response rates, treatment guide-
lines, and reimbursements. RESULTS: A total of 908 articles
were identiﬁed, of which 107 studies from North America ful-
ﬁlled the inclusion criteria (humanistic burden, N = 45; economic
burden, N = 49; and treatment guidelines, N = 13). Analysis of
these studies identiﬁed an increased humanistic and economic
burden in patients with MDD and TRD in North America. MDD
was associated with a high prevalence (3–31%), was chronic in
nature, and had a high frequency of comorbid mental disorders.
Health-related quality of life (HRQL) instruments identiﬁed a
signiﬁcant negative impact from MDD, including domains of
mental well-being (independence, alertness, role emotional,
personal/spiritual beliefs) and perceived physical functioning
(energy and fatigue, bodily care). In a study that compared
HRQL in responders and non-responders to therapy, HRQL was
signiﬁcantly lower in non-responders (P < 0.001). Patients with
TRD were particularly severely affected, through higher medical
costs and greater losses in work productivity. CONCLUSION:
Patients with MDD and their families suffer greater humanistic
and economic burden than healthy individuals. Treatment
reduces the burden of MDD, although current evidence-based
guidelines for MDD offer limited recommendations on the choice
of pharmacological treatments based on their potential to reduce
burden of illness and resource use.
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OBJECTIVE: Though antipsychotics were originally developed
to treat schizophrenia, their use in older adults with dementia has
grown substantially. Given concern about the safety of these
drugs, we assessed the impact of a prior authorization (PA) policy
upon use and choice of antipsychotic medication in long-term
care. METHODS: We conducted a retrospective cohort study
using administrative data from two Canadian provinces—one in
which access to newer antipsychotics (risperidone, olanzapine,
and quetiapine) was unrestricted (Ontario), and another in which
access required PA (British Columbia (BC)). Subjects were all
37,057 Ontario and 13,569 BC residents aged 66 years or older
who were newly admitted to a nursing home between April 1,
1998 and March 31, 2002, who had no history of schizophrenia
or psychosis in the 5 years preceding admission, and who had no
evidence of antipsychotic drug use in the preceding year. We
assessed crude and adjusted exposure to antipsychotic medica-
tion over the year following nursing home admission, as well as
the types of medications used. RESULTS: Nineteen percent of
Ontario residents were newly dispensed an antipsychotic within
100 days of nursing home admission vs. 16% in BC. Male sex,
younger age, fewer comorbidities, and history of dementia all
were strongly associated with receipt of an antipsychotic. Adjust-
ment for these factors reduced the cross-provincial difference in
drug use. However, fewer BC residents received newer anti-
psychotics, particularly after risperidone received an approved
indication for the management of behavioural symptoms of
dementia. Olanzapine, which required PA throughout the study,
was dispensed to 11% and 3% of Ontario and BC residents,
respectively. CONCLUSION: Although BC’s PA policy had neg-
ligible impact upon the incidence of antipsychotic drug use as a
whole, it appeared to inﬂuence drug choice. Questions remain
about the impact of such policies upon health outcomes and
costs.
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OBJECTIVE: The 2002 Veterans Health Care Act raised medi-
cation copayments from $2 to $7 for lower priority patients.
Veterans with schizophrenia constitute a multiply disadvantaged
population; 40% are antipsychotic non-adherent, substantially
increasing psychiatric admission risks. Certain patient sub-
groups might be particularly sensitive to medication costs with
signiﬁcant clinical ramiﬁcations. Diverse cultural expressions of
health beliefs and priorities contribute additional layers of com-
plexity. This study examines potential inequities stemming from
higher copayments. METHODS: All veterans with schizophrenia
were followed 33 months Pre and Post copayment increase.
Longitudinal models analyzed effects of higher medication costs
in copayment veterans versus a natural control group of exempt
patients, controlling for demographics, substance abuse, func-
tional status, and other comorbidities. Adjusted means compared
prescription patterns and inpatient utilization among four ethnic
groups: white (N = 36,452), African-American (N = 17,602),
Hispanic (N = 5,225), and Other (N = 10,707). RESULTS:
African-Americans were relatively younger with higher substance
abuse rates. Hispanic veterans were more likely to be unmarried
and have multiple illnesses, though fewer (39%) faced copay-
ments than other patients. Minorities ﬁlled 10–35% fewer pre-
scriptions than white veterans, and ethnic differences were
evident in pharmacy ﬁlls and inpatient days. White veterans
reduced psychotropic ﬁlls 15% after the policy change, decreas-
ing hospital days by nearly the same amount. However, mi-
norities dropped psychotropics 19%–22% while subsequently
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